LAS VEGAS—Bisphosphonate treatment in women with non-dialysis dependent chronic kidney disease (NDD-CKD) is associated with a decreased risk of death, but not of cardiovascular events, according to data presented at the National Kidney Foundation’s Spring Clinical Meetings.
James Hartle, MD, and coworkers at Geisinger Medical Center in Danville, Pa., enrolled 9,604 female patients with NDD-CKD. Of these, 3,234 received treatment with bisphosphonates. The median follow-up was 3.2 and 4.2 years in the treated and untreated groups, respectively. Compared with untreated patients, bisphosphonate recipients had a significant 21% decreased mortality risk after adjusting for age, smoking status, blood pressure, and other variables.
“Our cohort—an older female, CKD population with a relatively low burden of baseline cardiovascular disease—is not necessarily representative of the overall U.S. population with CKD, and may in part explain the discrepancy between the mortality and cardiovascular outcomes,” the authors noted in their poster presentation.